NDA 021501 · Loreal USA
Capital Soleil 15
Avobenzone, Ecamsule, Octocrylene · Topical
Last checked: Nov 20, 2026Latest source record: Feb 21, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Oct 2, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CAPITAL SOLEIL 15 · AVOBENZONE 2%; ECAMSULE 3%; OCTOCRYLENE 10% · CREAM, TOPICAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Avobenzone" as an intervention, any sponsor and status, largest first.
Food and Drug Administration (FDA)Federal agency
NCT03582215 · 72 participants · Start Jul 18, 2018 · Primary completion Feb 18, 2019
Drug: Part 1: Cream; Part 1: Lotion and 6 more · For: Systemic Exposure to Sunscreen Ingredients
Sites: West Bend, Wisconsin
Universidad Autonoma de San Luis PotosíAcademic, hospital or other
NCT01695356 · 68 participants · Start Sep 2012 · Primary completion Oct 2013
Drug: 290-400 nm sunscreen; 290-800 nm sunscreen · For: Melasma
Sites: San Luis Potosí City, Mexico
Yale UniversityAcademic, hospital or other
NCT05736224 · 30 participants · Start May 15, 2023 · Primary completion Sep 1, 2023
Drug: Sunscreen · For: Skin Cancer
Sites: New Haven, Connecticut
University of California, DavisAcademic, hospital or other
NCT05865431 · 17 participants · Start Mar 17, 2017 · Primary completion Feb 2, 2018
Drug: Zinc Oxide and Avobenzone · For: Sun Damaged Skin
Sites: Sacramento, California
- Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01001975 · 10 participants · Start Jul 2009 · Primary completion Aug 2009
Drug: Sunscreen Test Code: V53-028; Sunscreen Test Code: V53-030 and 1 more · For: Sun Protection
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial.
Matta MK, Florian J, Zusterzeel R, et al. · JAMA 2020 · Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.
- Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial.
Matta MK, Zusterzeel R, Pilli NR, et al. · JAMA 2019 · Clinical Trial, Phase I, Randomized Controlled Trial
- A systematic review and ecological risk assessment for organic ultraviolet filters in aquatic environments.
Carve M, Nugegoda D, Allinson G, et al. · Environ Pollut 2021 · Systematic Review
- Novel simultaneous method for the determination of avobenzone and oxybenzone in human plasma by UHPLC-MS/MS with phospholipid removal pretreatment: An application to a sunscreen clinical trial.
Pilli NR, Narayanasamy S, Florian J, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2021 · Randomized Controlled Trial
- Sun protection strength of a hydroquinone 4%/retinol 0.3% preparation containing sunscreens.
Stanfield JW, Feldman SR, Levitt J · J Drugs Dermatol 2006 · Clinical Trial, Comparative Study
- Combination of retinyl palmitate and UV-filters: phototoxic risk assessment based on photostability and in vitro and in vivo phototoxicity assays.
Benevenuto CG, Guerra LO, Gaspar LR · Eur J Pharm Sci 2015 · Controlled Clinical Trial
Sponsor: Loreal USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.